19 Lofton H, Ard JD, Hunt RR, Knight MG
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), widely used for metabolic disorders, have emerged as promising candidates for a range of neuropsychiatric conditions due to their broad neurobiological effects
Each study was evaluated across five domains as follows: bias arising from the randomization process, deviations from intended interventions, missing outcome data, measurement of the outcome, and selection of the reported result
For patients with type 2 diabetes, Ozempic (semaglutide) can be a valuable part of their treatment regimen, as a glucagon-like peptide-1 (GLP-1) receptor agonist, Ozempic works by enhancing the bodys natural insulin response, helping to lower blood sugar levels and promote weight loss